Zika virus pathogenesis and current therapeutic advances.

Abstract

Zika virus (ZIKV) is an emerging arthropod-borne flavivirus that, upon infection, results in teratogenic effects and neurological disorders. ZIKV infections pose serious global public health concerns, prompting scientists to increase research on antivirals and vaccines against the virus. These efforts are still ongoing as the pathogenesis and immune evasion mechanisms of ZIKV have not yet been fully elaborated. Currently, no specific vaccines or drugs have been approved for ZIKV; however, some are undergoing clinical trials. Notably, several strategies have been used to develop antivirals, including drugs that target viral and host proteins. Additionally, drug repurposing is preferred since it is less costly and takes less time than other strategies because the drugs used have already been approved for human use. Likewise, different platforms have been evaluated for the design of vaccines, including DNA, mRNA, peptide, protein, viral vectors, virus-like particles (VLPSs), inactivated-virus, and live-attenuated virus vaccines. These vaccines have been shown to induce specific humoral and cellular immune responses and reduce viremia and viral RNA both in vitro and in vivo. Importantly, most of these vaccines have entered clinical trials. Understanding the viral disease mechanism will provide better strategies for developing therapeutic agents against ZIKV. This review provides a comprehensive summary of the viral pathogenesis of ZIKV and current advancements in the development of vaccines and drugs against this virus.

• Authors: Caroline Mwaliko, Raphael Nyaruaba, Lu Zhao, Evans Atoni, Samuel Karungu, Matilu Mwau, Dimitri Lavillette, Han Xia, Zhiming Yuan
• Journal: Pathogens and global health (Pathog Glob Health) Vol. 115 Issue 1 Pg. 21-39 (02 2021) ISSN: 2047-7732 [Electronic] England
• PMID: 33191867 (Publication Type: Journal Article, Review)

Chemical References

• Antiviral Agents
• RNA, Viral
• Vaccines, Attenuated
• Viral Vaccines

Topics

• Antiviral Agents (pharmacology)
• Clinical Trials as Topic
• Drug Repositioning
• Humans
• RNA, Viral
• Vaccines, Attenuated
• Viral Vaccines
• Zika Virus (pathogenicity)
• Zika Virus Infection (drug therapy, prevention & control)